SandboxAQ Integrates Drug Discovery AI Model into Claude

Challenges in Drug Discovery and AI’s Potential

Drug discovery remains one of the most costly failures in modern industries. Identifying a promising molecule can take up to 10 years and cost billions of dollars, with most candidates failing to reach commercialization. While generations of AI startups have pledged to solve this problem, many have only succeeded in easing challenges for researchers already equipped with advanced technology. SandboxAQ believes the bottleneck lies not in the models but in the interfaces.

SandboxAQ’s Integration with Claude

SandboxAQ has partnered with Anthropic to directly integrate its scientific AI model into Claude. This integration allows powerful drug discovery and material science tools to be accessed via a conversational interface, eliminating the need for specialized computational infrastructure. SandboxAQ spun out from Alphabet approximately five years ago, with former Google CEO Eric Schmidt serving as chairman. The company has raised over $950 million from investors and operates multiple business lines, including cybersecurity.

LQMs: Physics-Based Large Quantitative Models

One of SandboxAQ’s signature initiatives is the development of Large Quantitative Models (LQMs). These proprietary models are “physics-based,” constructed not on textual patterns but on the rules of the physical world. They can perform quantum chemistry calculations, simulate molecular dynamics, and explore microkinetics (the unfolding of chemical reactions at the molecular level). As a result, researchers can predict the behavior of candidate molecules before entering the laboratory. LQMs are described as AI models designed for the quantitative economy, encompassing over $50 trillion across industries such as biopharma, financial services, energy, and advanced materials.

Improving Accessibility is Key

Previously, using SandboxAQ’s LQMs required users to provide their own digital infrastructure. Customers were computational scientists, research scientists, or experimentalists affiliated with major pharmaceutical or industrial companies, exploring new materials that could become marketable products. SandboxAQ’s AI Simulation General Manager, Nadia Hagen, stated, “For the first time, frontier quantitative models are accessible on a frontier LLM via natural language.” Unlike companies such as Chai Discovery and Isomorphic Labs, which focus on building better models, SandboxAQ prioritizes who can actually use them.

Impact on the Industry

The integration with Claude enables researchers without computational expertise to leverage advanced quantitative models, potentially accelerating the drug discovery process. SandboxAQ’s approach targets economies in need of transformation by AI, with accessibility democratization being a pivotal factor.